Lonza Group AG (LONN.SW) SIX
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Lonza Group AG
Address
Muenchensteinerstrasse 38
Basel, BS 4002
Switzerland
Phone
41 61 316 81 11
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18289
First IPO Date
November 01, 1999
Key Executives
| Name | Title | Pay | Year Born |
| Wolfgang Wienand | Chief Executive Officer | 2.17M | 1972 |
| Jean-Christophe Hyvert | President of Biologics Division | 0 | 1972 |
| Nicoleta Baumgartner | Chief Human Resources Officer | 0 | 1971 |
| David Carter | Head of Communications | 0 | N/A |
| Philippe Deecke | Chief Financial Officer | 0 | N/A |
| Jennifer Clancy | Senior Director of Global Marketing | 0 | N/A |
| Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility | 0 | N/A |
| Andreas Bohrer | Chief Legal & Corporate Affairs Officer | 0 | N/A |
| Victoria Morgan | Head of External Communications | 0 | N/A |
| Christian Seufert | President of Capsules & Health Ingredients Division | 0 | 1975 |
| Daniel Buchta | Head of Investor Relations | 0 | N/A |
| Gordon Bates | President of Small Molecules Division | 0 | 1965 |
| Jason Berndt | Executive Vice President & Head of Group Operations | 0 | N/A |
| Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability | 0 | N/A |
Description
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
